Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

NCT05890976 · Completed

Last updated 2026-05-28

This study is testing how well semaglutide tablets taken once daily work to help reduce body weight in Chinese adults who are above a healthy weight range.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 200 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-05 · est. completion 2025-01

Where 16 sites · China

What this study is testing ClinicalTrials.gov NCT05890976 ↗

Description as written by the study sponsor.

This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks. In addition to taking the medicine, participants will have talks with study staff about: * Healthy food choices * How to be more physically active * What participants can do to lose weight This study will last for about 1 year.

Treatments tested

Semaglutide Drug

Participants will receive semaglutide tablets orally once daily for 44 weeks.
Semaglutide Placebo Drug

Participants will receive placebo matched to semaglutide.

Main thing measured	Relative Change in Body Weight
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05890976 ↗